The integration of FTO expression into multivariable prognostic models, alongside established markers like IDH status and MGMT promoter methylation, could potentially enhance risk stratification and guide personalized treatment decisions for glioma patients (Brat et al., 2015). The gene discussed is MGMT; the disease is central nervous system cancer.